• LEARN MORE ABOUT KEYNOTE 695
  • About
    • About
    • Join The Team
    • Management Team
  • Pipeline
  • Technology
    • Technology
    • Tavo
    • VLA
    • Combination Approach
    • Publications
  • Partnering
  • Patients
    • Patients
    • Resources
    • Expanded Access
    • Together Against Cancer
  • Investors
  • Media
  • Contact
OncoSec Medical Incorporated
  • About
    • About
    • Join The Team
    • Management Team
  • Pipeline
  • Technology
    • Technology
    • Tavo
    • VLA
    • Combination Approach
    • Publications
  • Partnering
  • Patients
    • Patients
    • Resources
    • Expanded Access
    • Together Against Cancer
  • Investors
  • Media
  • Contact

Press Releases

Investors

Investors

  • Overview
    • Profile
    • Contacts
  • Events & Presentations
  • Analysts
  • Press Releases
    • Email Alerts
  • Financial Info
  • Stock Info
    • Quote
    • Charts
    • Historical Data
  • Filings
    • All SEC Filings
    • Annual Reports
    • Quarterly Reports
    • Section 16 Filings
  • Governance
    • Board of Directors
    • Board Committees
    • Governance Documents
  • FAQ
  • Press Releases

  • Email Alerts

OncoSec Presents Pre-Clinical Data from Its Visceral Lesion Applicator (VLA) and APOLLO Feasibility Study Demonstrating TAVO™ Can Be Safely Delivered and Electroporated in Liver at the Online Society of Interventional Radiology Annual Meeting

Apr 21, 2020 9:00am EDT

OncoSec Appoints Renowned Oncologist and Immunologist, Herbert Kim Lyerly, M.D., Duke University, to its Board of Directors

Apr 20, 2020 9:00am EDT

OncoSec Collaborates with Providence Cancer Institute to Conduct First-in-Human Trial of OncoSec's CORVax12, an Investigational Vaccine to Prevent COVID-19, Combining an Enhanced "Spike" DNA Sequence and TAVO™

Apr 06, 2020 9:00am EDT

OncoSec Announces Publication of Positive TAVO™ Monotherapy Results in Metastatic Melanoma Patients in Annals of Oncology

Mar 17, 2020 8:30am EDT

OncoSec Receives $850,000 from The Australian Research and Development (R&D) Tax Incentive Program for TAVO™ R&D Work in 2019

Mar 11, 2020 8:30am EDT

OncoSec Announces that the Class Action and Related Litigation Brought by Alpha Holdings Have Been Dismissed by Nevada State Court with Prejudice

Mar 09, 2020 8:30am EDT

OncoSec Strengthens its Board of Directors with Three New Appointments

Feb 11, 2020 8:30am EST

OncoSec Announces Closing of the CGP/Sirtex Transaction

Feb 10, 2020 8:30am EST

OncoSec Announces that Shareholders Have Approved CGP/Sirtex Transaction

Feb 07, 2020 10:53am EST

OncoSec Announces that Nevada Court Denies Alpha Holdings’ Motion to Enjoin Special Meeting of Shareholders

Feb 07, 2020 8:00am EST
RSS
  • Prev
    • 1...
    • 2
    • 3
    • 4
    • 5
    • 6
    • 7
    • 8
    • 9
    • 10
    • 11
    • ...46
    Next
    • Email Alerts
    • Contacts
    • RSS News Feed
    logo

    Sign Up for our mailing list to stay current on all of our exciting new research and developments.

    Get Email Alerts
    OncoSec’s investigational products have not been approved or cleared by the FDA.

    Links

    • About
    • Pipeline
    • Technology
    • Partnering
    • Patients
    • Media
    • Investors
    • Contact
    • KEYNOTE 695 CLINICAL TRIAL

    Contact

    New Jersey Headquarters
    820 Bear Tavern Road
    Suite 200
    Ewing, NJ 08628

    R&D Laboratories
    3565 General Atomics Court #100
    San Diego, CA 92121

    p | 855.662.6732
    f | 858.430.3832

    Investors@OncoSec.com


    © 2023 OncoSec Medical Incorporated. All Rights Reserved. Q12-003052-01 REV E.